Skip to main content

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies

Objective

Deep lying tumours like aggressive brain cancer remain very difficult to treat and existing therapies offer only marginal increase in survival rates. In the case of photomedical therapies they are very effective, but mainly limited by their insufficient depth of light penetration into tissue. Current neutron-based therapies have sufficient penetration depth but suffer from lack of cancer specificity. In FRINGE we propose a genuinely new hybrid-technology. At its heart are chemical agents (photosensitisers - PS) which preferentially accumulate in the tumours especially in brain cancers where the blood brain barrier is compromised. The PSs designed for FRINGE will contain metal centres like Gadolinium (Gd), to enable interaction with incoming neutrons and facilitate the transfer of neutron energy into electron excitation of the PS, confirmed by concomitant fluorescence emission. Interaction with ambient oxygen will generate reactive oxygen species which will kill the tumour cells. The main scientific breakthrough of this project will be to establish experimental proof-of-principle of this novel neutron-activated therapy. FRINGE will combine the advantages of photomedical therapies (no mutagenic radiation) with the advantages of neutron-based therapies (large penetration depth). The externally-applied neutron beam can be energy-tuned to become therapeutic exactly at the depth of the tumour. Exploiting Gd as a contrast agent, FRINGE can also become a theranostic modality by use of magnetic resonance imaging. FRINGE has the potential of causing immunogenic cell death to cancers which could eliminate occult metastasis and act as a ‘cancer vaccine’. The highly interdisciplinary project team comprises world renowned experts from a unique combination of disciplines: Nuclear physicists, synthetic chemists, photochemists, photobiologists, medical physicists, quantum chemists and radio-oncologists will join forces to lay the foundations for a novel, curative cancer therapy.

Field of science

  • /natural sciences/chemical sciences/inorganic chemistry/inorganic compounds
  • /medical and health sciences/clinical medicine/radiology/medical imaging/magnetic resonance imaging
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

H2020-FETOPEN-2018-2019-2020-01
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

OSLO UNIVERSITETSSYKEHUS HF
Address
Kirkeveien 166 Tarnbygget
0450 Oslo
Norway
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 898 118,75

Participants (7)

"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""
Greece
EU contribution
€ 719 687,50
Address
End Of Patriarchou Grigoriou E And 27 Neapoleos Street
15341 Agia Paraskevi
Activity type
Research Organisations
UNIVERSITAT DE GIRONA
Spain
EU contribution
€ 336 250
Address
Placa Sant Domenec 3
17004 Girona
Activity type
Higher or Secondary Education Establishments
SYNTHETICA AS
Norway
EU contribution
€ 446 875
Address
4 Etasje Silurveien 2B
0380 Oslo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE
Czechia
EU contribution
€ 382 500
Address
Technicka 5
166 28 Praha
Activity type
Higher or Secondary Education Establishments
UNIVERSITAT POLITECNICA DE VALENCIA
Spain
EU contribution
€ 384 375
Address
Camino De Vera Sn Edificio 3A
46022 Valencia
Activity type
Higher or Secondary Education Establishments
INSTITUTT FOR ENERGITEKNIKK
Norway
EU contribution
€ 559 875
Address
Instituttveien 18
2027 Kjeller
Activity type
Research Organisations
ACCELOPMENT SCHWEIZ AG
Switzerland
EU contribution
€ 251 803,75
Address
Seefeldstrasse 198
8008 Zurich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)